← SynDRA
CMS-024-02
SynDRA canonical compound SYN1958725 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Primary target(s) | PIK3CA |
|---|
| Mechanism of action | antitumor agent |
|---|
| Indication | hepatocellular carcinoma (hcc) |
|---|
| Disease area | oncology |
|---|
All known targets
Mechanisms of action (all sources)
Cross-references
Synonyms
- Tyroserleutide
- Tyroservatide
- CMS-024
- CMS-024)
- Tyroserleutide (iv, cancer), China Medical System
- Tyroserleutide (iv, cancer), Shenzhen Kangzhe Pharmaceuticals
- Tyroservatide (cancer), Shenzhen Kangzhe Pharmaceuticals/ China Medical System Holdings
- Tyroserleutide (iv, cancer), Shenzhen Kangzhe Pharmaceuticals/ China Medical System
- Tyrosyl-seryl-leucine (cancer), Tianjin Medical University/Shenzhen Kangzhe Pharmaceutical
Look up CMS-024-02 in the interactive SynDRA portal →